Haemonetics (NYSE:HAE) Price Target Lowered to $95.00 at Barrington Research

Haemonetics (NYSE:HAE) had its price target trimmed by Barrington Research from $108.00 to $95.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

Several other research analysts also recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Finally, Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Price Performance

NYSE HAE opened at $59.34 on Friday. The company has a 50 day simple moving average of $76.38 and a 200-day simple moving average of $78.32. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39. Haemonetics has a 52-week low of $59.09 and a 52-week high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts predict that Haemonetics will post 4.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. raised its position in shares of Haemonetics by 3.8% during the third quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after purchasing an additional 180 shares during the period. Arizona State Retirement System increased its stake in shares of Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock worth $1,160,000 after purchasing an additional 181 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 244 shares during the period. Finally, Keene & Associates Inc. grew its position in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock valued at $818,000 after purchasing an additional 298 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.